OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.
OBJECTIVE
To evaluate ocular hypertension (OHT) after Ozurdex injection to determine the incidence of OHT, therapy for OHT, and any associative factors such as diagnosis, underlying glaucoma and therapy, or sequential Ozurdex injection(s).


METHODS
Retrospective consecutive case series with patients receiving one or more intravitreal Ozurdex implantations at a tertiary care academic center. Ocular hypertension was defined as a single measurement of ≥30 mmHg or an increase of ≥10 mmHg from baseline.


RESULTS
Ninety-four injections in 52 patients (59 eyes) were reviewed. Forty eyes received a single injection, and 19 eyes received multiple injections. Ocular hypertension developed in 14 patients (26.9%). Thirteen patients (25%) had preexisting glaucoma or suspicion of glaucoma, and 6 of these developed OHT. Glaucoma eye drops were initiated after 13 injections (13.8%). Invasive surgery for glaucoma was required in 3 patients (3.2%): all had glaucoma or suspicion of glaucoma (one case was related to neovascular glaucoma and unlikely related to steroid response after Ozurdex). There was no difference in relative intraocular pressure increase (i.e., difference between final follow-up or subsequent intravitreal injection vs. baseline) between single versus multiple Ozurdex injections (P = 0.883).


CONCLUSIONS
Patients (26.9%) who received Ozurdex developed OHT. Glaucoma or glaucoma-suspicion factors were present in all patients who required invasive surgery for glaucoma. A greater proportion of patients who received multiple injections had an intraocular pressure elevation, but the relative intraocular pressure increase was not significant.
*Department of Ophthalmology and Visual Sciences, Vitreoretinal Service, Omics Laboratory, University of Iowa, Iowa City, Iowa; †Retina Consultants of Southern California, Redlands, California; ‡VitreoRetinal Surgery PA, Minneapolis, Minnesota; and §Department of Ophthalmology, Queen's University, Kingston, Ontario, Canada.
Eric K
EK
Chin
David R P
DRP
Almeida
Gabriel
G
Velez
Kunyong
K
Xu
Maria
M
Peraire
Maria
M
Corbella
Yasser M
YM
Elshatory
Young H
YH
Kwon
Karen M
KM
Gehrs
H Culver
HC
Boldt
Elliott H
EH
Sohn
Stephen R
SR
Russell
James C
JC
Folk
Vinit B
VB
Mahajan
D003692:Delayed-Action Preparations; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced* / Q000503:physiopathology; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors
D003692:Delayed-Action Preparations; D003907:Dexamethasone